Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes

Keyphrases

• Dipeptidyl peptidase-IV (DPP-IV) 100%
• Type 2 Diabetes Mellitus (T2DM) 100%
• Dipeptidyl peptidase-4 (DPP-4) 75%
• Incretin Hormones 50%
• Immune Function 25%
• Blood Glucose 25%
• Hyperglycemia 25%
• Cell Growth 25%
• Glucose-dependent Insulinotropic Polypeptide 25%
• Glucagon-like 25%
• Cell Adhesion 25%
• Dipeptide 25%
• Non-insulin 25%
• Insulin Independence 25%
• Tolerability 25%
• Insulinotropic Effects 25%
• Antidiabetic Effect 25%
• Serine Protease 25%
• Gliptins 25%
• Incretin 25%
• Protease Enzyme 25%
• New Treatment Options 25%
• Hormone Concentration 25%
• Prandial 25%
• Safe Control 25%
• Sustained Control 25%
• Long-term Clinical Study 25%
• Endocrine Function 25%
• Cell Metabolism 25%

Medicine and Dentistry

• Dipeptidyl Peptidase IV 100%
• Maturity Onset Diabetes of the Young 100%
• Dipeptidyl Peptidase-4 Inhibitor 100%
• Incretin 75%
• Receptor 25%
• Amino Terminal Sequence 25%
• Antidiabetic Activity 25%
• Gastric Inhibitory Polypeptide 25%
• Clinical Trial 25%
• Glucagon Like Peptide 1 25%
• Hyperglycemia 25%
• Blood Glucose 25%
• Cell Adhesion 25%
• Cell Growth 25%
• Immune Function 25%
• Serine Proteinase 25%
• Cleft 25%
• Cell Metabolism 25%
• Dipeptide 25%
• Insulin Like Activity 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Insulin Dependent Diabetes Mellitus 100%
• Dipeptidyl Peptidase IV 100%
• Dipeptidyl Peptidase IV Inhibitor 100%
• Incretin 75%
• Receptor 25%
• Hyperglycemia 25%
• Gastric Inhibitory Polypeptide 25%
• Antidiabetic Agent 25%
• Glucagon-Like Peptide-1 25%
• Dipeptide 25%
• Clinical Trial 25%
• Tolerability 25%
• Serine Proteinase 25%